Business Description
Neurizon Therapeutics Ltd
ISIN : AU0000357261
Total Employee Number:
52Description
Neurizon Therapeutics Ltd is a clinical-stage biotech company that develops drug discovery intellectual property for the treatment of different types of neurodegenerative diseases. Its product pipeline is NUZ-001 (S-Monepantel).
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 4.89 | |||||
Equity-to-Asset | 0.54 | |||||
Debt-to-Equity | 0.2 | |||||
Debt-to-EBITDA | -0.11 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -109.9 | |||||
3-Year EPS without NRI Growth Rate | -87.6 | |||||
3-Year FCF Growth Rate | -93.5 | |||||
3-Year Book Growth Rate | -37 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 57.4 | |||||
9-Day RSI | 48.39 | |||||
14-Day RSI | 47.07 | |||||
3-1 Month Momentum % | -26.83 | |||||
6-1 Month Momentum % | -33.33 | |||||
12-1 Month Momentum % | -64.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.18 | |||||
Quick Ratio | 2.18 | |||||
Cash Ratio | 1.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.8 | |||||
Shareholder Yield % | -23.1 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -193.59 | |||||
ROA % | -126.48 | |||||
ROIC % | -2707.4 | |||||
3-Year ROIIC % | 226.58 | |||||
ROC (Joel Greenblatt) % | -1491.06 | |||||
ROCE % | -193.44 | |||||
Moat Score | 2 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 4.14 | |||||
Price-to-Tangible-Book | 3.1 | |||||
EV-to-EBIT | -2.81 | |||||
EV-to-EBITDA | -2.81 | |||||
EV-to-FCF | -2.3 | |||||
| Price-to-Net-Current-Asset-Value | 3.1 | |||||
| Price-to-Net-Cash | 6.2 | |||||
Earnings Yield (Greenblatt) % | -35.53 | |||||
FCF Yield % | -36.32 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Neurizon Therapeutics Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.03 | ||
| Beta | 2.0038 | ||
| 3-Year Sharpe Ratio | 0.18 | ||
| 3-Year Sortino Ratio | 0.36 | ||
| Volatility % | 38.31 | ||
| 14-Day RSI | 47.07 | ||
| 14-Day ATR (A$) | 0.003212 | ||
| 20-Day SMA (A$) | 0.064075 | ||
| 12-1 Month Momentum % | -64.71 | ||
| 52-Week Range (A$) | 0.055 - 0.17 | ||
| Shares Outstanding (Mil) | 775.1 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Neurizon Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Neurizon Therapeutics Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| 0.05:1 Stock Split | 2015-10-30 | 0.10 (+0.00%) | ||
| 0.2:1 Stock Split | 2004-11-15 | 3.62 (+0.00%) |
Show
Entries
Neurizon Therapeutics Ltd Frequently Asked Questions
What is Neurizon Therapeutics Ltd(ASX:NUZ)'s stock price today?
The current price of ASX:NUZ is A$0.06. The 52 week high of ASX:NUZ is A$0.17 and 52 week low is A$0.06.
When is next earnings date of Neurizon Therapeutics Ltd(ASX:NUZ)?
The next earnings date of Neurizon Therapeutics Ltd(ASX:NUZ) is .
Does Neurizon Therapeutics Ltd(ASX:NUZ) pay dividends? If so, how much?
Neurizon Therapeutics Ltd(ASX:NUZ) does not pay dividend.
Press Release
Articles on Neurizon Therapeutics Ltd
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers